Histrelin Acetate
FDA-approved product (injectable, injection), marketed as Supprelin, Supprelin La, Vantas.
- Registered studies
- 13
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
- Prostate adenocarcinoma
- Prostate cancer
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Gonadotropin releasing hormone analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
13registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Histrelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
NCT06378866 · start 2024-06-03
Registered record
- Registry ID
- NCT06378866
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma
- Interventions
- Abiraterone; Apalutamide; Biospecimen Collection; Bone Scan; Computed Tomography; Darolutamide; Degarelix; Enzalutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Prednisone; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Radiation Therapy; Image-Guided Therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2024-06-03
- Completion
- 2031-02-28
- Enrolment
- 532
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate CarcinomaInterventionAbiraterone; Apalutamide; Biospecimen Collection; Bone Scan +17 morePhasePhase 2Registry statusRecruitingA Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
NCT05149131 · start 2022-01-17
Registered record
- Registry ID
- NCT05149131
- Conditions
- Metastatic Castration-sensitive Prostate Cancer
- Interventions
- ADT (Eligard®*) with or without treatment intensification
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2022-01-17
- Completion
- 2022-08-16
- Enrolment
- 960
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Castration-sensitive Prostate CancerInterventionADT (Eligard®*) with or without treatment intensificationPhaseNot recordedRegistry statusCompletedTwo Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084 · start 2021-12-06
Registered record
- Registry ID
- NCT05050084
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Bicalutamide; Buserelin; Darolutamide; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Radiation Therapy; Relugolix; Triptorelin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2021-12-06
- Completion
- 2031-11-11
- Enrolment
- 2,050
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate AdenocarcinomaInterventionBicalutamide; Buserelin; Darolutamide; Degarelix +7 morePhasePhase 3Registry statusActive not recruitingVeterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744 · start 2021-07-01
Registered record
- Registry ID
- NCT04787744
- Conditions
- Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer
- Interventions
- PET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide; Degarelix & Relugolix; ADT + Docetaxel +/- prednisone; ADT + Abiraterone + Prednisone; ADT + Abiraterone + Methylprednisolone; ADT + Apalutamide; ADT + Enzalutamide; Prostate-directed Radiation for De novo oligometastatic prostate cancer
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Recruiting
- Start
- 2021-07-01
- Completion
- 2029-03-30
- Enrolment
- 464
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer +2 moreInterventionPET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin +8 morePhasePhase 2 / Phase 3Registry statusRecruitingTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717 · start 2021-01-21
Registered record
- Registry ID
- NCT04513717
- Conditions
- Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2021-01-21
- Completion
- 2038-12-31
- Enrolment
- 2,753
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 morePhasePhase 3Registry statusActive not recruitingSkeletal Health and Bone Marrow Composition Among Youth
NCT04203381 · start 2020-09-15
Registered record
- Registry ID
- NCT04203381
- Conditions
- Gender Dysphoria in Children; Puberty; Bone Development
- Interventions
- GnRH Agonist
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2020-09-15
- Completion
- 2026-03-30
- Enrolment
- 78
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGender Dysphoria in Children; Puberty; Bone DevelopmentInterventionGnRH AgonistPhaseNot applicableRegistry statusTerminatedStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025 · start 2018-09-24
Registered record
- Registry ID
- NCT03678025
- Conditions
- Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone; Bicalutamide; Degarelix; Docetaxel; Flutamide; Goserelin Acetate; Histrelin Acetate; Leuprolide Acetate; Nilutamide; Orchiectomy; Prednisone; Quality-of-Life Assessment; Radiation Therapy; Radical Prostatectomy; Triptorelin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2018-09-24
- Completion
- 2031-10-01
- Enrolment
- 1,273
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 moreInterventionAbiraterone; Bicalutamide; Degarelix; Docetaxel +11 morePhasePhase 3Registry statusRecruitingThe Relation of GnRH Treatment to QTc Interval in Transgender Females
NCT03078829 · start 2017-05-01
Registered record
- Registry ID
- NCT03078829
- Conditions
- Gender Dysphoria
- Interventions
- Treatment with a GnRh agonists
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Terminated
- Start
- 2017-05-01
- Completion
- 2017-08-21
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGender DysphoriaInterventionTreatment with a GnRh agonistsPhaseNot recordedRegistry statusTerminatedEnzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
NCT02278185 · start 2015-11-11
Registered record
- Registry ID
- NCT02278185
- Conditions
- Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
- Interventions
- Enzalutamide; leuprolide acetate; goserelin acetate; histrelin acetate; triptorelin; degarelix
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-11-11
- Completion
- 2024-07-18
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate CancerInterventionEnzalutamide; leuprolide acetate; goserelin acetate; histrelin acetate +2 morePhasePhase 2Registry statusCompletedVantas Implant Retrieval Study
NCT01013025 · start 2006-07
Registered record
- Registry ID
- NCT01013025
- Conditions
- Prostate Cancer
- Interventions
- Ultrasound or CT or MRI to locate implant
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-07
- Completion
- 2007-06
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionUltrasound or CT or MRI to locate implantPhaseNot recordedRegistry statusCompletedHistrelin Subcutaneous Implant in Children With Central Precocious Puberty
NCT00779103 · start 2004-09
Registered record
- Registry ID
- NCT00779103
- Conditions
- Central Precocious Puberty
- Interventions
- Histrelin Subcutaneous Implant
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2012-04
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCentral Precocious PubertyInterventionHistrelin Subcutaneous ImplantPhasePhase 3Registry statusCompletedStudy of Histrelin Subdermal Implant in Patients With Prostate Cancer
NCT01394263 · start 2000-05
Registered record
- Registry ID
- NCT01394263
- Conditions
- Prostate Cancer; Adenocarcinoma of the Prostate
- Interventions
- Histrelin hydrogel implant; Zoladex goserelin implant
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-05
- Completion
- 2003-12
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; Adenocarcinoma of the ProstateInterventionHistrelin hydrogel implant; Zoladex goserelin implantPhasePhase 3Registry statusCompletedStudy to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
NCT01697384 · start 2000-04
Registered record
- Registry ID
- NCT01697384
- Conditions
- Prostate Cancer; Adenocarcinoma of the Prostate
- Interventions
- histrelin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-04
- Completion
- 2004-10
- Enrolment
- 138
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; Adenocarcinoma of the ProstateInterventionhistrelin acetatePhasePhase 3Registry statusCompleted